Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


Effectiveness of anti-VEGF agents in patients with retinal vein occlusion

Vyacheslav Yuryevich Mykhaylichenko; Anatoly Vladimirovich Kubyshkin; Alexey Sergeevich Ivashchenko; Sergey Alexandrovich Samarin; Golde Ogbonna; Ivan Ivanovich Fomochkin;

Retinal vein occlusion is a significant medical problem that requires urgent correction. We conducted a prospective observational study (n=124 patients) to investigate the efficacy of anti-vascular endothelial growth factor therapy (intravitreal injections of aflibercept 2 mg in 0.05 mL) compared with standard treatment in patients with retinal vein occlusion. When post-thrombotic neovascular glaucoma occurred, the concentrations of transforming growth factor α and β in the lacrimal fluid in both groups (with and without aflibercept) increased by 1.7-fold and 28-fold, respectively. When aflibercept was administered, the blood flow rates in ophthalmic and central retinal arteries, as well as the maximum velocity in the superior ophthalmic and central retinal veins, were improved compared with patients who received standard therapy. Thus, aflibercept therapy for retinal vein occlusion leads to the normalization of blood flow in retinal vasculature, preventing neovascularization and providing a better clinical outcome for patients.


1. Rogers S., McIntosh R. L., Cheung N. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319. https://doi.org/10.1016/j.ophtha.2009.07.017
2. Bradshaw S. E., Gala S., Nanavaty M., Shah A., Mwamburi M., Kefalas P. Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. BMC Ophthalmology. 2016;16:104. https://doi.org/10.1186/s12886-016-0282-5
3. Gerding H., Monés J., Tadayoni R., Boscia F., Pearce I.[et al.] Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. The British Journal of Ophthalmology. 2015;99(3):297-304. https://doi.org/10.1136/bjophthalmol-2014-305041
4. Reshak J., Reshak M. Branch retinal vein occlusion:pathogenesis, visual prognosis, and treatment modalities. Curr. Eyes Res. 2008;33:111–131. https://doi.org/10.1080/02713680701851902
5. Mohamed Q., McIntosh R. L., Saw S. M., Wong T. Y. Interventions for central retinal vein occlusion: an evidencebased systematic review. Ophthamology. 2007;114:507–519. https://doi.org/10.1016/j.ophtha.2006.11.011
6. Group CVOS. A randomised clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group N Report. Ophthalmology. 1995;102(10):1434–1444. https://doi.org/10.1016/S0161-6420(95)30848-2
7. Demir M., Dirim B., Acar Z., Sendul Y., Oba E. Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. Indian Journal of Ophthalmology. 2014;62(3):279-283. https://doi.org/10.4103/0301-4738.105769
8. Senturk F., Ozdemir H., Karacorlu M., Karacorlu S. A., Uysal O. Retinal sensitivity improvement after intravitreal triamcinolone acetonide injection for macular edema secondary to branch retinal vein occlusion. Indian Journal of Ophthalmology. 2013;61(1):3-7. https://doi.org/10.4103/0301-4738.105048
9. Jumper J. M., Dugel P. U., Chen S., Blinder K. J., Walt J. G. Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clin. Ophthalmol. 2018;3(12):621-629. https://doi.org/10.2147/OPTH.S163859
10. Scott I. U., VanVeldhuisen P. C., Ip M. S., Blodi B. A., Oden N. L. [et al.] Effect of Bevacizumab vs. Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA. 2017;317(20):2072-2087. https://doi.org/10.1001/jama.2017.4568
11. Campa C., Alivernini G., Bolletta E., Parodi M. B., Perri P. Anti-VEGF Therapy for Retinal Vein Occlusions. Curr Drug Targets. 2016;17(3):328-36. https://doi.org/10.2174/1573399811666150615151324
12. Mykhaylichenko V. Yu., Kubyshkin A. V., Samarin S. A.,Fomochkina I. I., Anisimova L. V. Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells. Pathophysiology. 2016;23(2):95-104. https://doi.org/10.1016/j.pathophys.2016.04.002
13. Fong A. H., Lai T. Y. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clinical Interventions in Aging. 2013;8:467-483. https://doi.org/10.2147/CIA.S36811
14. Mansour A. M., Al-Ghadban S. I., Yunis M. H., El-Sabban M. E. Ziv-aflibercept in macular disease. The British Journal of Ophthalmology. 2015;99(8):1055-1059. https://doi.org/10.1136/bjophthalmol-2014-306319
15. Campochiaro P. A, Clark W. L., Boyer D. S. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538–544. https://doi.org/10.1016/j.ophtha.2014.08.031
16. Ferrara N. VEGF and Intraocular Neovascularization: From Discovery to Therapy. Transl. Vis. Sci. Technol. 2016;5(2):10. Published online. https://doi.org/10.1167/tvst.5.2.10
17. Campochiaro P. A. Ocular neovascularization. J. Mol. Med. (Berl). 2013;91:311-321. https://doi.org/10.1007/s00109-013-0993-5
18. Li J., Paulus Y. M., Shuai Y., Fang W., Liu Q. [et al.] New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion. Journal of Ophthalmology. 2017;2017:4936924. https://doi.org/10.1155/2017/4936924
19. Hikichi T., Higuchi M., Matsushita T. Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. The British Journal of Ophthalmology. 2014;98(2):195-199. https://doi.org/10.1136/bjophthalmol-2013-303121
20. Gallego-Pinazo R., Dolz-Marco R., Marín-Lambíes C., Díaz-Llopis M. Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion. Ophthalmology and Eye Diseases. 2012;4:15-21. https://doi.org/10.4137/OED.S7264
21. Song W., Xia X. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment. BMC Ophthalmology. 2015;15:31. https://doi.org/10.1186/s12886-015-0017-z
22. Yoo S. J., Kim J. H., Lee T. G., Kim J. W., Cho S. W. [et al.] Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion. Korean Journal of Ophthalmology: KJO. 2017;31(2):95-101. https://doi.org/10.3341/kjo.2017.31.2.95
23. Phipps J. A., Clermont A. C., Sinha S., Chilcote T. J., Bursell S-E. [et al.] Plasma kallikrein mediates angiotensin at1 receptor stimulated retinal vascular permeability. Hypertension (Dallas, Tex: 1979). 2009;53(2):175-181. https://doi.org/10.1161/hypertensionaha.108.117663
24. Hayreh S. S. Ocular vascular occlusive disorders: Natural history of visual outcome. Progress in retinal and eye research. 2014;41:1-25. https://doi.org/10.1016/j.preteyeres.2014.04.001
25. Pożarowska D., Pożarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Central-European Journal of Immunology. 2016;41(3):311-316. https://doi.org/10.5114/ceji.2016.63132

Keywords: central retinal vein occlusion, anti-angiogenic therapy, optical coherence tomography, angiography

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy